Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Delafloxacin
    • 1.4.3 Vancomycin
    • 1.4.4 Ceftaroline Fosamil
    • 1.4.5 Others
  • 1.5 Market by Application
    • 1.5.1 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Share by Application: 2020 VS 2026
    • 1.5.2 Cellulitis
    • 1.5.3 Abscess
    • 1.5.4 Surgical Wounds
    • 1.5.5 Traumatic Wound
  • 1.6 Coronavirus Disease 2019 (Covid-19): Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Industry
      • 1.6.1.1 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Perspective (2015-2026)
  • 2.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Growth Trends by Regions
    • 2.2.1 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Players by Market Size
    • 3.1.1 Global Top Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Concentration Ratio
    • 3.2.1 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Revenue in 2019
  • 3.3 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players Head office and Area Served
  • 3.4 Key Players Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Product Solution and Service
  • 3.5 Date of Enter into Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Forecasted Market Size by Type (2021-2026)

5 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)
  • 5.2 Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size (2015-2020)
  • 6.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players in North America (2019-2020)
  • 6.3 North America Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Type (2015-2020)
  • 6.4 North America Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size (2015-2020)
  • 7.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players in Europe (2019-2020)
  • 7.3 Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Type (2015-2020)
  • 7.4 Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)

8 China

  • 8.1 China Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size (2015-2020)
  • 8.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players in China (2019-2020)
  • 8.3 China Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Type (2015-2020)
  • 8.4 China Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size (2015-2020)
  • 9.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players in Japan (2019-2020)
  • 9.3 Japan Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Type (2015-2020)
  • 9.4 Japan Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size (2015-2020)
  • 10.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)

11 India

  • 11.1 India Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size (2015-2020)
  • 11.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players in India (2019-2020)
  • 11.3 India Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Type (2015-2020)
  • 11.4 India Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size (2015-2020)
  • 12.2 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Type (2015-2020)
  • 12.4 Central & South America Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Furiex Pharmaceuticals, Inc.
    • 13.1.1 Furiex Pharmaceuticals, Inc. Company Details
    • 13.1.2 Furiex Pharmaceuticals, Inc. Business Overview and Its Total Revenue
    • 13.1.3 Furiex Pharmaceuticals, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.1.4 Furiex Pharmaceuticals, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020))
    • 13.1.5 Furiex Pharmaceuticals, Inc. Recent Development
  • 13.2 GlaxoSmithKline plc
    • 13.2.1 GlaxoSmithKline plc Company Details
    • 13.2.2 GlaxoSmithKline plc Business Overview and Its Total Revenue
    • 13.2.3 GlaxoSmithKline plc Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.2.4 GlaxoSmithKline plc Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.2.5 GlaxoSmithKline plc Recent Development
  • 13.3 Melinta Therapeutics, Inc.
    • 13.3.1 Melinta Therapeutics, Inc. Company Details
    • 13.3.2 Melinta Therapeutics, Inc. Business Overview and Its Total Revenue
    • 13.3.3 Melinta Therapeutics, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.3.4 Melinta Therapeutics, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.3.5 Melinta Therapeutics, Inc. Recent Development
  • 13.4 Debiopharm International S.A.
    • 13.4.1 Debiopharm International S.A. Company Details
    • 13.4.2 Debiopharm International S.A. Business Overview and Its Total Revenue
    • 13.4.3 Debiopharm International S.A. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.4.4 Debiopharm International S.A. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.4.5 Debiopharm International S.A. Recent Development
  • 13.5 MerLion Pharmaceuticals Pte Ltd.
    • 13.5.1 MerLion Pharmaceuticals Pte Ltd. Company Details
    • 13.5.2 MerLion Pharmaceuticals Pte Ltd. Business Overview and Its Total Revenue
    • 13.5.3 MerLion Pharmaceuticals Pte Ltd. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.5.4 MerLion Pharmaceuticals Pte Ltd. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.5.5 MerLion Pharmaceuticals Pte Ltd. Recent Development
  • 13.6 Durata Therapeutics, Inc.
    • 13.6.1 Durata Therapeutics, Inc. Company Details
    • 13.6.2 Durata Therapeutics, Inc. Business Overview and Its Total Revenue
    • 13.6.3 Durata Therapeutics, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.6.4 Durata Therapeutics, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.6.5 Durata Therapeutics, Inc. Recent Development
  • 13.7 Paratek Pharmaceuticals, Inc.
    • 13.7.1 Paratek Pharmaceuticals, Inc. Company Details
    • 13.7.2 Paratek Pharmaceuticals, Inc. Business Overview and Its Total Revenue
    • 13.7.3 Paratek Pharmaceuticals, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.7.4 Paratek Pharmaceuticals, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.7.5 Paratek Pharmaceuticals, Inc. Recent Development
  • 13.8 Cempra, Inc.
    • 13.8.1 Cempra, Inc. Company Details
    • 13.8.2 Cempra, Inc. Business Overview and Its Total Revenue
    • 13.8.3 Cempra, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.8.4 Cempra, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.8.5 Cempra, Inc. Recent Development
  • 13.9 Abbott Laboratories, Inc.
    • 13.9.1 Abbott Laboratories, Inc. Company Details
    • 13.9.2 Abbott Laboratories, Inc. Business Overview and Its Total Revenue
    • 13.9.3 Abbott Laboratories, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.9.4 Abbott Laboratories, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.9.5 Abbott Laboratories, Inc. Recent Development
  • 13.10 Actelion Pharmaceuticals Ltd.
    • 13.10.1 Actelion Pharmaceuticals Ltd. Company Details
    • 13.10.2 Actelion Pharmaceuticals Ltd. Business Overview and Its Total Revenue
    • 13.10.3 Actelion Pharmaceuticals Ltd. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 13.10.4 Actelion Pharmaceuticals Ltd. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 13.10.5 Actelion Pharmaceuticals Ltd. Recent Development
  • 13.11 Albany Molecular Research, Inc.
    • 10.11.1 Albany Molecular Research, Inc. Company Details
    • 10.11.2 Albany Molecular Research, Inc. Business Overview and Its Total Revenue
    • 10.11.3 Albany Molecular Research, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.11.4 Albany Molecular Research, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.11.5 Albany Molecular Research, Inc. Recent Development
  • 13.12 Allergan plc.
    • 10.12.1 Allergan plc. Company Details
    • 10.12.2 Allergan plc. Business Overview and Its Total Revenue
    • 10.12.3 Allergan plc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.12.4 Allergan plc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.12.5 Allergan plc. Recent Development
  • 13.13 AstraZeneca
    • 10.13.1 AstraZeneca Company Details
    • 10.13.2 AstraZeneca Business Overview and Its Total Revenue
    • 10.13.3 AstraZeneca Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.13.4 AstraZeneca Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.13.5 AstraZeneca Recent Development
  • 13.14 Bayer AG
    • 10.14.1 Bayer AG Company Details
    • 10.14.2 Bayer AG Business Overview and Its Total Revenue
    • 10.14.3 Bayer AG Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.14.4 Bayer AG Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.14.5 Bayer AG Recent Development
  • 13.15 Macrolide Pharmaceuticals, Inc.
    • 10.15.1 Macrolide Pharmaceuticals, Inc. Company Details
    • 10.15.2 Macrolide Pharmaceuticals, Inc. Business Overview and Its Total Revenue
    • 10.15.3 Macrolide Pharmaceuticals, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.15.4 Macrolide Pharmaceuticals, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.15.5 Macrolide Pharmaceuticals, Inc. Recent Development
  • 13.16 Merck & Co, Inc.
    • 10.16.1 Merck & Co, Inc. Company Details
    • 10.16.2 Merck & Co, Inc. Business Overview and Its Total Revenue
    • 10.16.3 Merck & Co, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.16.4 Merck & Co, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.16.5 Merck & Co, Inc. Recent Development
  • 13.17 Pfizer, Inc.
    • 10.17.1 Pfizer, Inc. Company Details
    • 10.17.2 Pfizer, Inc. Business Overview and Its Total Revenue
    • 10.17.3 Pfizer, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.17.4 Pfizer, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.17.5 Pfizer, Inc. Recent Development
  • 13.18 Sanofi
    • 10.18.1 Sanofi Company Details
    • 10.18.2 Sanofi Business Overview and Its Total Revenue
    • 10.18.3 Sanofi Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.18.4 Sanofi Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.18.5 Sanofi Recent Development
  • 13.19 Teva Pharmaceuticals Industries Ltd.
    • 10.19.1 Teva Pharmaceuticals Industries Ltd. Company Details
    • 10.19.2 Teva Pharmaceuticals Industries Ltd. Business Overview and Its Total Revenue
    • 10.19.3 Teva Pharmaceuticals Industries Ltd. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.19.4 Teva Pharmaceuticals Industries Ltd. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.19.5 Teva Pharmaceuticals Industries Ltd. Recent Development
  • 13.20 Zavante Therapeutics, Inc.
    • 10.20.1 Zavante Therapeutics, Inc. Company Details
    • 10.20.2 Zavante Therapeutics, Inc. Business Overview and Its Total Revenue
    • 10.20.3 Zavante Therapeutics, Inc. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Introduction
    • 10.20.4 Zavante Therapeutics, Inc. Revenue in Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Business (2015-2020)
    • 10.20.5 Zavante Therapeutics, Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Furiex Pharmaceuticals, Inc.
    GlaxoSmithKline plc
    Melinta Therapeutics, Inc.
    Debiopharm International S.A.
    MerLion Pharmaceuticals Pte Ltd.
    Durata Therapeutics, Inc.
    Paratek Pharmaceuticals, Inc.
    Cempra, Inc.
    Abbott Laboratories, Inc.
    Actelion Pharmaceuticals Ltd.
    Albany Molecular Research, Inc.
    Allergan plc.
    AstraZeneca
    Bayer AG
    Macrolide Pharmaceuticals, Inc.
    Merck & Co, Inc.
    Pfizer, Inc.
    Sanofi
    Teva Pharmaceuticals Industries Ltd.
    Zavante Therapeutics, Inc.

    Market segment by Type, the product can be split into
    Delafloxacin
    Vancomycin
    Ceftaroline Fosamil
    Others
    Market segment by Application, split into
    Cellulitis
    Abscess
    Surgical Wounds
    Traumatic Wound

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment status, future forecast, growth opportunity, key market and key players.
    To present the Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now